File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer

TitleResults of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer
Authors
Wu, YLLu, SLu, YZhou, JYShui, YKSriuranpong, VHo, JCMOng, CKTsai, CMChung, CHWilner, KDTang, YMasters, ETSelaru, PMok, TS
KeywordsALK-positive advanced non–small cell lung cancer
chemotherapy
crizotinib
phase III
Issue Date2018
PublisherElsevier Inc. The Journal's web site is located at http://www.jto.org
Citation
Journal of Thoracic Oncology, 2018, v. 13, p. 1539-1548 How to Cite?
DOI: http://dx.doi.org/10.1016/j.jtho.2018.06.012
Persistent Identifierhttp://hdl.handle.net/10722/264228
ISSN
1556-0864
2021 Impact Factor: 20.121
2020 SCImago Journal Rankings: 4.539
ISI Accession Number ID
WOS:000445154800023

 

DC FieldValueLanguage
dc.contributor.authorWu, YL-
dc.contributor.authorLu, S-
dc.contributor.authorLu, Y-
dc.contributor.authorZhou, JY-
dc.contributor.authorShui, YK-
dc.contributor.authorSriuranpong, V-
dc.contributor.authorHo, JCM-
dc.contributor.authorOng, CK-
dc.contributor.authorTsai, CM-
dc.contributor.authorChung, CH-
dc.contributor.authorWilner, KD-
dc.contributor.authorTang, Y-
dc.contributor.authorMasters, ET-
dc.contributor.authorSelaru, P-
dc.contributor.authorMok, TS-
dc.date.accessioned2018-10-22T07:51:35Z-
dc.date.available2018-10-22T07:51:35Z-
dc.date.issued2018-
dc.identifier.citationJournal of Thoracic Oncology, 2018, v. 13, p. 1539-1548-
dc.identifier.issn1556-0864-
dc.identifier.urihttp://hdl.handle.net/10722/264228-
dc.languageeng-
dc.publisherElsevier Inc. The Journal's web site is located at http://www.jto.org-
dc.relation.ispartofJournal of Thoracic Oncology-
dc.subjectALK-positive advanced non–small cell lung cancer-
dc.subjectchemotherapy-
dc.subjectcrizotinib-
dc.subjectphase III-
dc.titleResults of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer-
dc.typeArticle-
dc.identifier.emailHo, JCM: jhocm@hku.hk-
dc.identifier.authorityHo, JCM=rp00258-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jtho.2018.06.012-
dc.identifier.scopuseid_2-s2.0-85051792172-
dc.identifier.hkuros294692-
dc.identifier.volume13-
dc.identifier.spage1539-
dc.identifier.epage1548-
dc.identifier.isiWOS:000445154800023-
dc.publisher.placeUnited States-
dc.identifier.issnl1556-0864-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats